CA2371434A1 - Compositions and methods for the treatment of tumor - Google Patents

Compositions and methods for the treatment of tumor Download PDF

Info

Publication number
CA2371434A1
CA2371434A1 CA002371434A CA2371434A CA2371434A1 CA 2371434 A1 CA2371434 A1 CA 2371434A1 CA 002371434 A CA002371434 A CA 002371434A CA 2371434 A CA2371434 A CA 2371434A CA 2371434 A1 CA2371434 A1 CA 2371434A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
antibody
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002371434A
Other languages
English (en)
French (fr)
Inventor
David A. Botstein
Audrey Goddard
Austin L. Gurney
Victoria Smith
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002504679A priority Critical patent/CA2504679A1/en
Priority to CA002501815A priority patent/CA2501815A1/en
Publication of CA2371434A1 publication Critical patent/CA2371434A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002371434A 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor Abandoned CA2371434A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002504679A CA2504679A1 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor
CA002501815A CA2501815A1 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US60/138,385 1999-06-09
US14479099P 1999-07-20 1999-07-20
US60/144,790 1999-07-20
US14684399P 1999-08-03 1999-08-03
US60/146,843 1999-08-03
US14818899P 1999-08-10 1999-08-10
US60/148,188 1999-08-10
US14932099P 1999-08-17 1999-08-17
US14932799P 1999-08-17 1999-08-17
US14939699P 1999-08-17 1999-08-17
US60/149,320 1999-08-17
US60/149,327 1999-08-17
US60/149,396 1999-08-17
US15011499P 1999-08-20 1999-08-20
US60/150,114 1999-08-20
US15173499P 1999-08-31 1999-08-31
US15170099P 1999-08-31 1999-08-31
US60/151,734 1999-08-31
US60/151,700 1999-08-31
PCT/US2000/013358 WO2000075317A2 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA002504679A Division CA2504679A1 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor
CA002501815A Division CA2501815A1 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor

Publications (1)

Publication Number Publication Date
CA2371434A1 true CA2371434A1 (en) 2000-12-14

Family

ID=27581055

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002371434A Abandoned CA2371434A1 (en) 1999-06-09 2000-05-15 Compositions and methods for the treatment of tumor

Country Status (8)

Country Link
EP (3) EP1657256B1 (enExample)
JP (5) JP2003501087A (enExample)
AT (2) ATE444971T1 (enExample)
AU (1) AU4851900A (enExample)
CA (1) CA2371434A1 (enExample)
DE (2) DE60043125D1 (enExample)
ES (2) ES2332916T3 (enExample)
WO (1) WO2000075317A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU1473801A (en) * 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 6 human secreted proteins
AU2463401A (en) * 1999-12-29 2001-07-09 Zymogenetics Inc. Novel fgf homolog zfgf10
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2004520005A (ja) * 2000-06-19 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー オステオレビン遺伝子多型性
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
AU5923398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
EP1032668B1 (en) * 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
KR20010086224A (ko) * 1998-01-23 2001-09-10 추후제출 Ｍｅｔｈ1 및 ｍｅｔｈ2 폴리뉴클레오티드 및 폴리펩티드
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Also Published As

Publication number Publication date
WO2000075317A3 (en) 2001-02-08
ES2331657T3 (es) 2010-01-12
EP1657256A3 (en) 2006-08-09
EP1185642A2 (en) 2002-03-13
JP4260778B2 (ja) 2009-04-30
EP1657256A2 (en) 2006-05-17
EP1683811A2 (en) 2006-07-26
JP2006006331A (ja) 2006-01-12
EP1657256B1 (en) 2009-10-07
EP1683811A3 (en) 2006-10-11
EP1683811B1 (en) 2009-08-19
JP2005027667A (ja) 2005-02-03
WO2000075317A2 (en) 2000-12-14
JP2003501087A (ja) 2003-01-14
ES2332916T3 (es) 2010-02-15
DE60043125D1 (de) 2009-11-19
ATE444971T1 (de) 2009-10-15
JP2006006330A (ja) 2006-01-12
AU4851900A (en) 2000-12-28
DE60042799D1 (de) 2009-10-01
ATE440109T1 (de) 2009-09-15
JP2006006332A (ja) 2006-01-12
JP4252501B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
AU2003200731C1 (en) Compositions and methods for the treatment of tumor
EP1683811B1 (en) Methods for the diagnosis of tumors
WO2000053755A2 (en) Compositions and methods for the treatment of tumor
AU773055B2 (en) Compositions and methods for the treatment of tumors
AU2004216245A1 (en) Methods for the treatment of renal cell carcinoma
WO2000037640A9 (en) Compositions and methods for the treatment of tumor
WO2001005836A1 (en) Polypeptidic compositions and methods for the treatment of tumors
AU756400B2 (en) Compositions and methods for the treatment of tumor
CA2478728A1 (en) Compositions and methods for the treatment of tumors
NZ513423A (en) Compositions and methods for the treatment of tumors
ZA200106059B (en) Compositions and methods for the treatment of tumors.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued